Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Net Margin (2019 - 2025)

Eton Pharmaceuticals' Net Margin history spans 7 years, with the latest figure at 5.04% for Q3 2025.

  • For Q3 2025, Net Margin fell 1111.0% year-over-year to 5.04%; the TTM value through Sep 2025 reached 9.5%, up 9.0%, while the annual FY2024 figure was 9.8%, 684.0% down from the prior year.
  • Net Margin for Q3 2025 was 5.04% at Eton Pharmaceuticals, up from 13.66% in the prior quarter.
  • Across five years, Net Margin topped out at 43.0% in Q1 2021 and bottomed at 786.32% in Q3 2021.
  • The 5-year median for Net Margin is 10.18% (2024), against an average of 70.85%.
  • The largest YoY upside for Net Margin was 2358427bps in 2021 against a maximum downside of -25621628bps in 2021.
  • A 5-year view of Net Margin shows it stood at 17.05% in 2021, then plummeted by -37bps to 10.73% in 2022, then crashed by -171bps to 7.57% in 2023, then surged by 32bps to 5.13% in 2024, then rose by 2bps to 5.04% in 2025.
  • Per Business Quant, the three most recent readings for ETON's Net Margin are 5.04% (Q3 2025), 13.66% (Q2 2025), and 104.8% (Q1 2025).